A self-adjuvanting vaccine induces cytotoxic Tlymphocytes that suppress allergy

Nature Chemical Biology

Volumn 10, Issue 11, 2014, Pages 943-949

  Anderson, Regan J ^a   Tang, Ching Wen ^b   Daniels, Naomi J ^b,c   Compton, Benjamin J ^a   Hayman, Colin M ^a   Johnston, Karen A ^a   Knight, Deborah A ^b   Gasser, Olivier ^b   Poyntz, Hazel C ^b   Ferguson, Peter M ^d   Larsen, David S ^e   Ronchese, Franca ^b   Painter, Gavin F ^a   Hermans, Ian F ^a,b  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 4; PEPTIDE VACCINE; TUMOR NECROSIS FACTOR ALPHA; ALLERGEN; ALPHA-GALACTOSYLCERAMIDE; ANTIINFLAMMATORY AGENT; GALACTOSYLCERAMIDE; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; PEPTIDE; PRODRUG; VACCINE;

ADJUVANT THERAPY; ALLERGIC AIRWAY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DRUG CONJUGATION; DRUG SYNTHESIS; FLOW CYTOMETRY; IN VITRO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THERAPY EFFECT; ANIMAL; ANTIGEN PRESENTING CELL; BLOOD; C57BL MOUSE; CHEMISTRY; CONFORMATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGEN-PRESENTING CELLS; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MOLECULAR CONFORMATION; NATURAL KILLER T-CELLS; PEPTIDES; PRODRUGS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES;

EID: 84924336773     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1640     Document Type: Article

References (57)

1. Janeway, C.A. Jr. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
2. Steinman, R.M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
3. Jackson, D.C. et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101, 15440-15445 (2004).
4. Khan, S. et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282, 21145-21159 (2007).
5. Oh, J.Z. & Kedl, R.M. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185, 4602-4608 (2010).
6. Ingale, S., Wolfert, M.A., Gaekwad, J., Buskas, T. & Boons, G.J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3, 663-667 (2007).
7. Tighe, H. et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30, 1939-1947 (2000).
8. Vecchi, S. et al. Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. Eur. J. Pharm. Biopharm. 87, 310-317 (2014).
9. Bennett, S.R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
10. Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478 (1998).
11. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R. & Melief, C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
12. Hunn, M.K. & Hermans, I.F. Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. Oncoimmunology 2, e23789 (2013).
13. Arase, H., Arase, N., Ogasawara, K., Good, R.A. & Onoé, K. An NK1.1+ CD4+8- single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V β family. Proc. Natl. Acad. Sci. USA 89, 6506-6510 (1992).
14. Lantz, O. & Bendelac, A. An invariant T cell receptor α chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180, 1097-1106 (1994).
15. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. & Steinman, R.M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279 (2003).
16. Gonzalez-Aseguinolaza, G. et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195, 617-624 (2002).
17. Hermans, I.F. et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171, 5140-5147 (2003).
18. Stober, D., Jomantaite, I., Schirmbeck, R. & Reimann, J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol. 170, 2540-2548 (2003).
19. Semmling, V. et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 11, 313-320 (2010).
20. Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255-281 (1999).
21. van Rijt, L.S. et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J. Exp. Med. 201, 981-991 (2005).
22. Enomoto, N. et al. Allergen-specific CTL require perforin expression to suppress allergic airway inflammation. J. Immunol. 188, 1734-1741 (2012).
23. Aguilar-Pimentel, J.A. et al. Specific CD8 T cells in IgE-mediated allergy correlate with allergen dose and allergic phenotype. Am. J. Respir. Crit. Care Med. 181, 7-16 (2010).
24. Wells, J.W., Cowled, C.J., Giorgini, A., Kemeny, D.M. & Noble, A. Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration. J. Allergy Clin. Immunol. 119, 226-234 (2007).
25. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997).
26. Pellicci, D.G. et al. Differential recognition of CD1d-α-galactosylceramide by the Vβ8.2 and Vβ7 semi-invariant NKT T cell receptors. Immunity 31, 47-59 (2009).
27. Alexander, J., Cargill, R., Michelson, S.R. & Schwam, H. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem. 31, 318-322 (1988).
28. Flechtner, J.B. et al. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses. J. Immunol. 177, 1017-1027 (2006).
29. Bendelac, A., Savage, P.B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336 (2007).
30. Farrand, K.J. et al. Langerin+ CD8α+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens. J. Immunol. 183, 7732-7742 (2009).
31. Mustapa, M.F.M. et al. Stabilized integrin-targeting ternary LPD (lipopolyplex) vectors for gene delivery designed to disassemble within the target cell. Bioconjug. Chem. 20, 518-532 (2009).
32. Elewaut, D. et al. The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Vα14i NKT cells. J. Exp. Med. 198, 1133-1146 (2003).
33. van den Elzen, P. et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437, 906-910 (2005).
34. Freigang, S. et al. Scavenger receptors target glycolipids for natural killer T cell activation. J. Clin. Invest. 122, 3943-3954 (2012).
35. Kitamura, H. et al. α-Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell. Immunol. 199, 37-42 (2000).
36. Galli, G. et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197, 1051-1057 (2003).
37. Lang, G.A., Exley, M.A. & Lang, M.L. The CD1d-binding glycolipid α-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 119, 116-125 (2006).
38. Miyahara, N. et al. Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nat. Med. 10, 865-869 (2004).
39. Erard, F., Wild, M.T., Garcia-Sanz, J.A. & Le Gros, G. Switch of CD8 T cells to noncytolytic CD8- CD4- cells that make TH2 cytokines and help B cells. Science 260, 1802-1805 (1993).
40. Cui, J. et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J. Exp. Med. 190, 783-792 (1999).
41. Hachem, P. et al. α-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-γ. Eur. J. Immunol. 35, 2793-2802 (2005).
42. Matsuda, H. et al. α-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am. J. Respir. Cell Mol. Biol. 33, 22-31 (2005).
43. Morishima, Y. et al. Suppression of eosinophilic airway inflammation by treatment with α-galactosylceramide. Eur. J. Immunol. 35, 2803-2814 (2005).
44. Kim, J.-O. et al. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. J. Allergy Clin. Immunol. 114, 1332-1338 (2004).
45. Meyer, E.H. et al. Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc. Natl. Acad. Sci. USA 103, 2782-2787 (2006).
46. Parekh, V.V. et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115, 2572-2583 (2005).
47. Lee, A. et al. Novel synthesis of α-galactosylceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr. Res. 341, 2785-2798 (2006).
48. Hogquist, K.A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27 (1994).
49. Pircher, H., Bürki, K., Lang, R., Hengartner, H. & Zinkernagel, R.M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342, 559-561 (1989).
50. Köntgen, F., Suss, G., Stewart, C., Steinmetz, M. & Bluethmann, H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol. 5, 957-964 (1993).
51. Chen, Y.H., Chiu, N.M., Mandal, M., Wang, N. & Wang, C.R. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity 6, 459-467 (1997).
52. Kissenpfennig, A. et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643-654 (2005).
53. Giaccone, G. et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702-3709 (2002).
54. Zajonc, D.M. et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6, 810-818 (2005).
55. Bendelac, A. et al. CD1 recognition by mouse NK1+ T lymphocytes. Science 268, 863-865 (1995).
56. Watson, J. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J. Exp. Med. 150, 1510-1519 (1979).
57. Roediger, B. et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat. Immunol. 14, 564-573 (2013).